ROS‐Responsive Hybrid Nanoparticles Enable Dual‐Target Neurovascular Repair via Blood–Brain Barrier‐on‐Chip Validation
Source abstract
Abstract
Abstract Blood–brain barrier leakage and neuronal damage are interconnected pathological features of neurovascular diseases. However, existing therapeutic strategies often fail to address both components simultaneously. Here, a reactive oxygen species‐responsive exosome–liposome hybrid nanoparticle is designed, which is capable of co‐delivering siBACH1 and siGSDMD for dual‐target gene therapy, aiming to concurrently mitigate neuronal oxidative stress and BBB pyroptosis. A major hurdle in neurotherapeutic development is the limited predictive accuracy of conventional in vitro BBB models, which often contributes to the translational gap between preclinical studies and clinical applications. To address this, a microfluidic blood‐brain barrier‐on‐chip platform incorporating endothelial cells, astrocytes, and neurons, which dynamically recapitulates key pathological hallmarks of MPTP‐induced neurovascular diseases, are developed. Both the blood‐brain barrier‐on‐chip platform and in vivo studies demonstrate the efficacy of the hybrid nanoparticles in synergistically restoring blood‐brain barrier integrity and neuronal function. By integrating a predictive blood‐brain barrier‐on‐chip with advanced nanotherapeutics, this work provides a dual‐target gene therapy strategy for synergistic neurovascular repair and proposes a new paradigm for precision intervention in neurovascular diseases.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Barrier Structure and Function Studies · Extracellular vesicles in disease · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Chemistry and Biological Engineering University of Science and Technology Beijing Beijing 100083 China
Daxing Research Institute University of Science and Technology Beijing Beijing 100083 China
Funding
National Natural Science Foundation of China · Key Research and Development Program of Hunan Province of China
References (50)
Show source-provided references
1. Wei C. · Nature · 2024 · 629 · 89310.1038/s41586-024-07314-2 ↗
2. Langen U. H. · Annu. Rev. Cell Dev. Biol. · 2019 · 35 · 59110.1146/annurev-cellbio-100617-062608 ↗
3. Zhang Q. S. · Acta Pharmacol. Sin. · 2017 · 38 · 131710.1038/aps.2017.49 ↗
4. Al‐Bachari S. · Front. Physiol. · 2020 · 1110.3389/fphys.2020.593026 ↗
5. Khor S. L. Q. · CNS Neurol Disord Drug Targets · 2024 · 23 · 31510.2174/1871527322666230330093829 ↗
6. Shen T. · Neural. Regen. Res. · 2024 · 19 · 137510.4103/1673-5374.385843 ↗
7. Khalid Iqbal M. · ACS Omega · 2024 · 910.1021/acsomega.4c06546 ↗
8. Wang Y. · Neural. Regen. Res. · 2024 · 21 · 37710.4103/NRR.NRR-D-23-01511 ↗
9. Wu X. · Asian J. Pharm. Sci. · 2024 · 19
10. An Y. · Cell Prolif · 2021 · 5410.1111/cpr.12993 ↗
11. Mustafa M. B. · Expert Opin. Drug Deliv. · 2025 · 22 · 170910.1080/17425247.2025.2556013 ↗
12. Gribkoff V. K. · Neuropharmacology · 2017 · 120 · 1110.1016/j.neuropharm.2016.03.021 ↗
13. Alteri E. · Nature · 2018 · 563 · 31710.1038/d41586-018-07352-7 ↗
14. Smith B. L. · Brain Behav. Immun. Health · 2021 · 1610.1016/j.bbih.2021.100294 ↗
15. Prasad T. · WIREs Mech Dis · 2023 · 1510.1002/wsbm.1603 ↗
16. Jhanji M. · Curr. Opin. Neurobiol. · 2024 · 8910.1016/j.conb.2024.102916 ↗
17. Bi W. · Ageing Res. Rev. · 2023 · 8710.1016/j.arr.2023.101921 ↗
18. Morris H. R. · Lancet · 2024 · 403 · 29310.1016/S0140-6736(23)01478-2 ↗
19. Blesa J. · Sci. Adv. · 2023 · 910.1126/sciadv.adf4888 ↗
20. Lau K. · Transl. Neurodegener · 2024 · 13 · 3710.1186/s40035-024-00430-z ↗
21. Ding X. S. · Ageing Res. Rev. · 2023 · 9110.1016/j.arr.2023.102077 ↗
22. Ahuja M. · Proc Natl Acad Sci U S A · 2021 · 11810.1073/pnas.2111643118 ↗
23. Ahuja M. · Antioxidants · 2022 · 11 · 178010.3390/antiox11091780 ↗
24. Huang P. · Mol. Neurobiol. · 2024 · 61 · 259010.1007/s12035-023-03713-0 ↗
25. Zhang X. · Brain Behav. Immun. · 2024 · 119 · 12910.1016/j.bbi.2024.03.038 ↗
26. Jackson‐Lewis V. · Nat. Protoc. · 2007 · 2 · 14110.1038/nprot.2006.342 ↗
27. Ahuja M. · J. Neurosci. · 2016 · 36 · 633210.1523/JNEUROSCI.0426-16.2016 ↗
28. Liu J. · J. Nanobiotechnology · 2022 · 20 · 21310.1186/s12951-022-01435-4 ↗
29. Jiang S. · ACS Nano · 2024 · 1810.1021/acsnano.3c13150 ↗
30. Zhang J. · Int. J. Nanomedicine · 2022 · 17 · 675910.2147/IJN.S374039 ↗
31. Cheng X. · Adv. Drug Deliv. Rev. · 2016 · 99 · 12910.1016/j.addr.2016.01.022 ↗
32. Qi D. · J. Control Release · 2023 · 358 · 7810.1016/j.jconrel.2023.04.020 ↗
33. Pandey M. · Expert Opin. Drug Discov. · 2024 · 19 · 30310.1080/17460441.2023.2293158 ↗
34. Conq J. · Biomedicines · 2024 · 12 · 109110.3390/biomedicines12051091 ↗
35. Hajal C. · Nat. Protoc. · 2022 · 17 · 9510.1038/s41596-021-00635-w ↗
36. Pediaditakis I. · Nat. Commun. · 2021 · 12 · 590710.1038/s41467-021-26066-5 ↗
37. Kim S. · Biomaterials · 2021 · 27910.1016/j.biomaterials.2021.121210 ↗
38. Rus Jacquet A. · Nat. Commun. · 2023 · 14 · 365110.1038/s41467-023-39038-8 ↗
39. Srinivasan B. · J. Lab Autom. · 2015 · 20 · 10710.1177/2211068214561025 ↗
40. Palma‐Florez S. · J. Nanobiotechnology · 2023 · 21 · 11510.1186/s12951-023-01798-2 ↗
41. Casares L. · Redox Biol. · 2020 · 3710.1016/j.redox.2020.101689 ↗
42. Wang B. · Acta Pharm. Sin. B · 2023 · 13 · 266310.1016/j.apsb.2023.04.008 ↗
43. Park S. E. · Science · 2019 · 364 · 96010.1126/science.aaw7894 ↗
44. Bhatia S. N. · Nat. Biotechnol. · 2014 · 32 · 76010.1038/nbt.2989 ↗
45. Lal R. · Eur. J. Pharmacol. · 2024 · 98010.1016/j.ejphar.2024.176819 ↗
46. Sun X. Y. · Elife · 2022 · 1110.7554/eLife.76707 ↗
47. Ran N. · Bioact Mater · 2023 · 25 · 766
48. Xu L. · ACS Nano · 2024 · 18
49. Kistemaker L. · Trends Biotechnol. · 2025 · 43 · 127510.1016/j.tibtech.2024.11.021 ↗
50. Boutom S. M. · Cell Rep. · 2024 · 4310.1016/j.celrep.2024.115068 ↗